Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL

Optimal management of patients with relapsed/refractory chronic lymphocytic leukemia (CLL) is dictated by patient characteristics, prior therapy, and response to prior therapy. We report the final analysis of combined fludarabine, cyclophosphamide, and rituximab (FCR) for previously treated patients...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Badoux, Xavier C., Keating, Michael J., Wang, Xuemei, O'Brien, Susan M., Ferrajoli, Alessandra, Faderl, Stefan, Burger, Jan, Koller, Charles, Lerner, Susan, Kantarjian, Hagop, Wierda, William G.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: American Society of Hematology 2011
Onderwerpen:
Clinical Trials and Observations
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4123386/
https://ncbi.nlm.nih.gov/pubmed/21245487
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-08-304683
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items